Sienna Cancer Diagnostics names interim CEO
Sienna Cancer Diagnostics has appointed an interim replacement to outgoing CEO Dr Kerry Hegarty.
Former Immune System Therapeutics CEO Dr Cliff Holloway assumed the role on Monday.
Holloway is also currently the Australasian representative for healthcare and chemical investment banking company Ferghana Partners Group and a director of biotech investment fund Newstar Ventures.
Hegarty stepped down as CEO last month after 10 years in the role, as part of Sienna’s long-term strategic transformation plan.
Sienna Chairman Dr Geoff Cumming said the board decided to appoint an interim CEO as quickly as possible while searching for a permanent replacement. Holloway is a possible candidate for the permanent position.
“The appointment of Cliff as an interim CEO will ensure the company has immediate access to a leader with the right mix of skills to guide Sienna into its next phase, and provide continuity through to the appointment of a permanent CEO,” he said.
“Dr Holloway is a high-calibre and well-regarded business leader; his strategic and tactical experience leading biotechnology companies through critical phases of their growth will be invaluable to Sienna. The board and I are looking forward to working with Cliff.”
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
